tetano
Editor, Senior Moderator
Clin Infect Dis. 2012 Mar 22. [Epub ahead of print]
A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans.
Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.
Source
Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Abstract
BackgroundThe novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a Phase I clinical study which demonstrated vaccine safety and immunogenicity, a Phase IIa vaccination and influenza challenge study has now been conducted in healthy adult volunteers.MethodsVolunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T cell responses to the vaccine antigens were measured at enrolment and again prior to virus challenge. All volunteers underwent intranasal administration of influenza A/Wisconsin/67/2005 whilst in a quarantine unit, and were monitored for symptoms of influenza disease and virus shedding.ResultsVolunteers had a significantly increased T cell response to the vaccine antigens following a single dose of the vaccine, with an increase in cytolytic effector molecules. Intranasal influenza challenge was undertaken without safety issues. Two of eleven vaccinees and five of eleven control subjects developed laboratory confirmed influenza (symptoms plus virus shedding). Symptoms of influenza were less pronounced in the vaccinees and there was a significant reduction in the number of days of virus shedding in those vaccinees who developed influenza (mean 1.09 days in controls, 0.45 days in vaccinees, p= 0.036).ConclusionsThis study provides the first demonstration of clinical efficacy of a T cell based influenza vaccine, and indicates that further clinical development should be undertaken.
PMID:
22441650
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22441650
A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans.
Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.
Source
Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Abstract
BackgroundThe novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a Phase I clinical study which demonstrated vaccine safety and immunogenicity, a Phase IIa vaccination and influenza challenge study has now been conducted in healthy adult volunteers.MethodsVolunteers with no measurable serum antibodies to influenza A/Wisconsin/67/2005 received either a single vaccination with MVA-NP+M1 or no vaccination. T cell responses to the vaccine antigens were measured at enrolment and again prior to virus challenge. All volunteers underwent intranasal administration of influenza A/Wisconsin/67/2005 whilst in a quarantine unit, and were monitored for symptoms of influenza disease and virus shedding.ResultsVolunteers had a significantly increased T cell response to the vaccine antigens following a single dose of the vaccine, with an increase in cytolytic effector molecules. Intranasal influenza challenge was undertaken without safety issues. Two of eleven vaccinees and five of eleven control subjects developed laboratory confirmed influenza (symptoms plus virus shedding). Symptoms of influenza were less pronounced in the vaccinees and there was a significant reduction in the number of days of virus shedding in those vaccinees who developed influenza (mean 1.09 days in controls, 0.45 days in vaccinees, p= 0.036).ConclusionsThis study provides the first demonstration of clinical efficacy of a T cell based influenza vaccine, and indicates that further clinical development should be undertaken.
PMID:
22441650
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22441650